摘要: Background: Metformin hydrochloride is widely used for the treatment of type 2 diabetes mellitus (DM-2). Todate, only cases possible metformin-induced hepatotoxicity (acute hepatitis) have been reported worldwide. Objective: The aim this article was to report a case serious possibly associated with metformin use in an elderly patient DM-2. Methods: After receiving 500 mg/d 3 weeks, 73-year-old Japanese woman weighing 33.S kg poorly controlled DM-2 presented fatigue, jaundice, nausea, vomiting, anorexia, and abdominal pain. Laboratory analysis showed severe (elevated aspartate alanine aminotransferases [AST ALT, respectively], alkaline phosphatase [ALP], total bilirubin concentrations). history, clinical findings, laboratory features, course case, as well pharmacologic profile metformin, are presented. Results: Immediate hospitalization discontinuation led improvements liver function (decreased AST, ALP, concentrations) resolution symptoms within weeks. probability adverse drug reaction (ADR), assessed using Naranjo ADR scale, 4 (probable). Conclusions: In who after3 weeks treatment, appeared caused mixed-type (hepatocellular cholestatic) hepatic damage. Although rare, might be some cases.
elsevier.com
sci-hub.se 参考文章(19)
Janelle C Nisbet, Joanna M Sturtevant, Johannes B Prins, Metformin and serious adverse effects. The Medical Journal of Australia. ,vol. 180, pp. 56- 56 ,(2004) , 10.5694/J.1326-5377.2004.TB05796.X
William L Isley, Hepatotoxicity of thiazolidinediones. Expert Opinion on Drug Safety. ,vol. 2, pp. 581- 586 ,(2003) , 10.1517/14740338.2.6.581
Keith G Tolman, Jane Chandramouli, Hepatotoxicity of the thiazolidinediones. Clinics in Liver Disease. ,vol. 7, pp. 369- 379 ,(2003) , 10.1016/S1089-3261(03)00020-5
A. M. Emslie-Smith, D. I. R. Boyle, J. M. M. Evans, F. Sullivan, A. D. Morris, , Contraindications to metformin therapy in patients with Type 2 diabetes--a population-based study of adherence to prescribing guidelines. Diabetic Medicine. ,vol. 18, pp. 483- 488 ,(2001) , 10.1046/J.1464-5491.2001.00509.X
Fadel E. Nammour, MD, Nabil F. Fayad, MD, Steven R. Peikin, MD, Metformin-induced cholestatic hepatitis. Endocrine Practice. ,vol. 9, pp. 307- 309 ,(2003) , 10.4158/EP.9.4.307
Dmitri Kirpichnikov, Samy I. McFarlane, James R. Sowers, Metformin: an update. Annals of Internal Medicine. ,vol. 137, pp. 25- 33 ,(2002) , 10.7326/0003-4819-137-1-200207020-00009
A. M. E. Stades, J. T. Heikens, D. W. Erkelens, F. Holleman, J. B. L. Hoekstra, Metformin and lactic acidosis: cause or coincidence? A review of case reports Journal of Internal Medicine. ,vol. 255, pp. 179- 187 ,(2004) , 10.1046/J.1365-2796.2003.01271.X
R. Giannarelli, M. Aragona, A. Coppelli, S. Del Prato, Reducing insulin resistance with metformin: the evidence today. Diabetes & Metabolism. ,vol. 29, ,(2003) , 10.1016/S1262-3636(03)72785-2
G C Jones, Contraindications to the use of metformin BMJ. ,vol. 326, pp. 4- 5 ,(2003) , 10.1136/BMJ.326.7379.4
C A Naranjo, U Busto, E M Sellers, P Sandor, I Ruiz, E A Roberts, E Janecek, C Domecq, D J Greenblatt, A method for estimating the probability of adverse drug reactions Clinical Pharmacology and Therapeutics. ,vol. 30, pp. 239- 245 ,(1981) , 10.1038/CLPT.1981.154